Markus Jensen
Impact in
- Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research
Papers in
- Genetics 4
- Chronic Lymphocytic Leukemia Research 3
-
- Monoclonal and Polyclonal Antibodies Research 5
- Radiopharmaceutical Chemistry and Applications 2
- Co-authors
- Heinz Mehlhorn (1 shared paper)Michael J. Hallek (2 shared papers)Frank Berthold (5 shared papers)Joachim Ludwig Schultze (3 shared papers)Matthias Kochanek (1 shared paper)Roman Kurt Thomas (1 shared paper)Svenja Debey (1 shared paper)Elmar Endl (1 shared paper)
- Journals
- Journal of Immunotherapy (3 papers)Journal of Clinical Oncology (2 papers)Blood (1 paper)Immunology Letters (1 paper)Parasitology Research (1 paper)
- Partner nations
- GermanyUnited StatesUnited Kingdom
In The Last Decade
Markus Jensen
14 papers receiving 1.3k citations
Markus Jensen's Hit Papers
Peers
Comparison fields: 5 of 74
- Hepatology 425
- Genetics 314
- Immunology 220
- Oncology 137
- Hematology 53
Countries citing papers authored by Markus Jensen
This map shows the geographic impact of Markus Jensen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Jensen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Jensen more than expected).
Fields of papers citing papers by Markus Jensen
This network shows the impact of papers produced by Markus Jensen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Jensen. The network helps show where Markus Jensen may publish in the future.
Co-authors
The 25 scholars most cited alongside Markus Jensen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma Hit paper breakdown → | 2014 | 495 |
| 2 | 2005 | 429 | |
| 3 | 2005 | 165 | |
| 4 | 2009 | 89 | |
| 5 | 2007 | 77 | |
| 6 | 2021 | 36 | |
| 7 | 2007 | 24 | |
| 8 | 2016 | 22 | |
| 9 | 1997 | 16 | |
| 10 | 2009 | 8 | |
| 11 | 2004 | 6 | |
| 12 | 2006 | 5 | |
| 13 | 2007 | 5 | |
| 14 | 2013 | 1 |
About Markus Jensen
Markus Jensen is a scholar working on Genetics, Radiology, Nuclear Medicine and Imaging, Immunology, Hepatology and Nephrology, having authored 14 papers that have together received 1.4k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (5 papers), Chronic Lymphocytic Leukemia Research (3 papers), Immunotherapy and Immune Responses (3 papers), Radiopharmaceutical Chemistry and Applications (2 papers), T-cell and B-cell Immunology (2 papers), Clinical Laboratory Practices and Quality Control (1 paper), Hemophilia Treatment and Research (1 paper) and Malaria Research and Control (1 paper). The work is most often cited by research in Hepatology (425 citations), Genetics (314 citations), Immunology (220 citations), Oncology (137 citations) and Hematology (53 citations). Markus Jensen has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Heinz Mehlhorn, Michael J. Hallek, Frank Berthold, Joachim Ludwig Schultze, Matthias Kochanek, Roman Kurt Thomas, Svenja Debey, Elmar Endl, Kamruz Darabi and Percy Alexander Knolle. Their work appears in journals such as Journal of Immunotherapy, Journal of Clinical Oncology, Blood, Immunology Letters and Parasitology Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.